What if there was a way to get an accurate medical diagnosis with your doctor, without having to send your test to a laboratory?

The Biosensor platform is a small, organic strip that will put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners.

Using Organic Thin Film Transistor (OTFT) technology, the Biosensor platform is currently in development to test for up to 130 indications, ranging from glucose for diabetes management, to immunological conditions and communicable diseases.

Currently, we are preparing for the launch of the Saliva Glucose Biosensor, the first iteration of our technology intended to replace finger-prick glucose testing for people living with diabetes.

The saliva glucose biosensor

Replacing the need for finger-prick blood testing

The Saliva Glucose Biosensor is the world’s first non-invasive, saliva-based glucose test for diabetes management that measure glucose in saliva, not blood. Our innovative technology will free people living with diabetes from having to use painful and invasive blood monitoring devices to manage their condition, giving them a better quality of life.

1
Bring the Saliva Glucose Biosensor in contact with saliva.
2
Move the biosensor to a smart device. The digital application displays glucose levels and flags measurements that need attention.
3
The digital application provides real-time comparisons against historical data and can transmit information remotely to points of care (electronic medical record, caregiver).

For illustrative purposes only and
has yet to receive regulatory
approval in any jurisdiction.

One Platform, Multiple diagnostic tests

Translational Medicine

Biochemistry

The pilot diagnostic test is Saliva Glucose. Diagnostic test portfolio includes Clinical Chemistry Tests (ie. Cholesterol).

Tumor Markers

This tumor marker test portfolio along with other tests was designed to help doctors diagnose cancer and plan treatment. Tumor markers can be used in guiding treatment decisions, monitoring treatment, predicting the chance of recovery, and predict or monitor for tumor recurrence.

Immunology

The pilot diagnostic test will be allergens (peanut kernel) and the portfolio will consist of various communicable disease tests including Hepatitis A, B & C, HIV and TORCH.

Hormones

The first test to be developed from a hormone category is Luteinizing Hormone (LH).

We are also exploring the application of the platform in Nucleic Acid analysis and its applications in personalized medicine.

Launch Market

GBS Inc.
The Saliva Glucose Biosensor will first launch in the Asia Pacific region, where more people live with diabetes than anywhere else in the world.

The purpose of this website is to provide a general overview of the business and the activities and services provided by those members of The iQ Group Global. This website is not intended to operate as an offer, solicitation or securities recommendation for the subscription or purchase of any securities or investments or advice on any securities.